IP Library Granted Patent US 10,751,397
Granted Patent B2
US 10,751,397 · App. 16/015,784 · Granted Aug 25, 2020

Regulatory T cell epitopes, compositions and uses thereof

Inventors: Anne De Groot (Providence, RI); William Martin (Cumberland, RI); Daniel S. Rivera (Marshfield, MA)
Assignee: EpiVax, Inc.
A61K39/0008C07K14/47C07K14/75C07K14/76C07K14/78C07K14/79A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,397
App. No.
16/015,784
Granted
Aug 25, 2020
Kind
B2
Abstract

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

Claims (10)

1. A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a T-cell epitope composition, wherein the T-cell epitope composition comprises one or more isolated T-cell epitope polypeptides, wherein at least one isolated T-cell epitope polypeptide consists of the amino acid sequence of SEQ ID NO: 5.

2. The method of claim 1 , wherein the T-cell epitope composition further comprises at least one isolated T-cell epitope polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 4 and 6-58.

3. The method of claim 1 , wherein the T-cell epitope composition further comprises at least one isolated T-cell epitope polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 4, 6, 10, 14, 23, 24 or 31.

4. The method of claim 1 , wherein the T-cell epitope composition further comprises an effective amount of one or more antigens and/or allergens.

5. The method of claim 1 , wherein the immune suppressive effect is mediated by natural regulatory T cells.

6. The method of claim 1 , wherein the immune suppressive effect is mediated by adaptive regulatory T-cells.

7. The method of claim 1 , wherein the T-cell epitope composition suppresses an effector T-cell response.

8. The method of claim 7 , wherein the T-cell epitope composition suppresses a cytokine secretion of effector T-cells.

9. The method of claim 1 , wherein the T-cell epitope composition suppresses a helper T-cell response.

10. The method of claim 1 , wherein the T-cell epitope composition suppresses a B-cell response.

Assignments (3)
SECURITY INTEREST Recorded Jun 30, 2026
From: EPIVAX, INC.; EPV INTERMEDIATE HOLDINGS, LLC
To: FIFTH THIRD BANK, N.A.
Reel/Frame 075141/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2018
From: DE GROOT, ANNE; MARTIN, WILLIAM
To: EPIVAX, INC.
Reel/Frame 047122/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2018
From: RIVERA, DANIEL S.
To: EPIVAX, INC.
Reel/Frame 047123/0120 →
Continuity (5)
Continuation 14857693 · Sep 17, 2015
Continuation 12981098 · Dec 29, 2010
Division 12021832 · Jan 29, 2008
Provisional Application 60898347 · Jan 30, 2007
Related Publication 20180289782A1 · Oct 11, 2018